Clinical Trial Update: Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) [NA]

View source ↗

Summary

Clinical trial update on evaluating lenalidomide (REVLIMID) for treating cutaneous lupus erythematosus; status completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: University of Pennsylvania | Conditions: Cutaneous Lupus Erythematosus (CLE) | NA | Status: COMPLETED | Results posted: 2019-11-13